ContraFect Corporation (CFRX) financial statements (2020 and earlier)

Company profile

Business Address 28 WELLS AVENUE
YONKERS, NY 10701
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments243047353327
Cash and cash equivalents248741026
Short-term investments 224031232
Other undisclosed current assets712110
Total current assets:313149363428
Noncurrent Assets
Operating lease, right-of-use asset3
Property, plant and equipment111122
Other noncurrent assets000000
Total noncurrent assets:411122
TOTAL ASSETS:353350383630
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities964445
Accounts payable311220
Accrued liabilities743323
Employee-related liabilities     2
Debt1     
Deferred revenue and credits   1
Other undisclosed current liabilities     (2)
Total current liabilities:1064444
Noncurrent Liabilities
Long-term debt and lease obligation3     
Operating lease, liability3
Liabilities, other than long-term debt622151410
Deferred revenue and credits111 
Deferred rent credit 1
Other liabilities000   
Derivative instruments and hedges, liabilities621141300
Total noncurrent liabilities:922151410
Total liabilities:1927191854
Stockholders' equity
Stockholders' equity attributable to parent16631203126
Common stock000000
Additional paid in capital228205193166148118
Accumulated other comprehensive loss (0)(0)(0)(0)(0)
Accumulated deficit(212)(199)(162)(146)(118)(92)
Total stockholders' equity:16631203126
TOTAL LIABILITIES AND EQUITY:353350383630

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Operating expenses(28)(31)(27)(34)(25)(17)
Operating loss:(28)(31)(27)(34)(25)(17)
Nonoperating income (expense)15(7)115(0)(13)
Other nonoperating expense  (1)(2)  
Interest and debt expense     (12)
Net loss:(13)(38)(16)(29)(25)(43)
Other undisclosed net income attributable to parent     12
Net loss attributable to parent:(13)(38)(16)(29)(25)(30)
Other undisclosed net loss available to common stockholders, basic     (4)
Net loss available to common stockholders, diluted:(13)(38)(16)(29)(25)(35)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(13)(38)(16)(29)(25)(43)
Other undisclosed comprehensive income     12
Comprehensive loss:(13)(38)(16)(29)(25)(30)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent00(0)(0)(0) 
Comprehensive loss, net of tax, attributable to parent:(13)(38)(16)(29)(25)(30)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: